Calviri immune checkpoint inhibitors
(ICI) diagnostic

Calviri’s immunotherapy diagnostic is a huge leap forward in predicting therapy outcomes compared to current available solutions.

Comparison of Calviri’s and current approach ICI assays

An established market with the need for biomarkers to improve effectiveness…


ICI estimated market size

Immune Checkpoint Inhibitors are a leading cancer treatment with estimated total addressable market estimated at $25 billion per year – and growing


Cancer patients eligible for ICI

Over 50% of all cancer patients are already eligible for ICI treatment

2 (with more to follow)


Calviri has established collaborations with two groups at MD Anderson, and are working on two others. Our preliminary results on renal cancer, and mixed rare cancers, using our Immunotherapy Response Predictor are positive – showing much improvement over the current standard


Average response

Currently available ICI treatments have an average response of only 20-30%, and up to 70% adverse events